Puma Biotechnology | PBYI - Current Assets


Puma Biotechnology reported $143.58M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Agios Pharmaceuticals USD 717.67M 117.18M Jun/2026
Alnylam Pharmaceuticals USD 4.62B 400.86M Jun/2026
Amgen USD 34.96B 3.49B Jun/2026
Biogen USD 7.31B 1.88B Jun/2026
BioMarin Pharmaceutical USD 3.97B 633.45M Jun/2026
Daiichi Sankyo JPY 2.23T 91.92B Jun/2026
Exelixis USD 1.25B 42.18M Jun/2026
Gilead Sciences USD 12.53B 6.11B Jun/2026
Glaxosmithkline GBP 17.76B 5.83B Mar/2026
Incyte USD 6.03B 542.31M Jun/2026
MacroGenics USD 321.69M 139.16M Jun/2026
Moderna USD 5.82B 45M Jun/2026
Novartis USD 27.35B 744M Jun/2026
Pfizer USD 41.36B 1.46B Jun/2026
PTC Therapeutics USD 2.62B 363.36M Jun/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Regeneron Pharmaceuticals USD 18.45B 236.8M Jun/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.22B 86.05M Jun/2026
Takeda JPY 3.15T 59.77B Jun/2026
TG Therapeutics USD 1.15B 58.72M Jun/2026
Ultragenyx Pharmaceutical USD 606M 51M Jun/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Vertex Pharmaceuticals USD 12.54B 813.4M Jun/2026